Cost of illness of metastatic prostate cancer: a perspective of costs for new treatment options in The Netherlands

There is no fulltext present in this item.

Title:	Cost of illness of metastatic prostate cancer: a perspective of costs for new treatment options in The Netherlands
Author(s):	Heine, R. ter ; Frederix, G.W.; Geenen, J.W.; Hovels, A.M.; Vulpen, M. van; Kooistra, A.; Klerk, J.M. de; Bloemendal, H.J.
Publication year:	2017
Source:	Journal of Comparative Effectiveness Research, vol. 6, iss. 7, (2017), pp. 575-581
ISSN:	2042-6305
DOI:	https://doi.org/10.2217/cer-2017-0026
Publication type:	Article / Letter to editor
Please use this identifier to cite or link to this item : https://hdl.handle.net/2066/182725
Display more details
Subject:	Radboudumc 4: lnfectious Diseases and Global Health RIHS: Radboud Institute for Health Sciences
Organization:	Clinical Pharmacy
Journal title:	Journal of Comparative Effectiveness Research
Volume:	vol. 6
Issue:	iss. 7
Page start:	p. 575
Page end:	p. 581
Abstract:	AIM: To assess the resource use and associated costs of treating patients with metastatic prostate cancer with a focus on skeletal-related events (SREs). METHODS: We performed a bottom-up cost of illness study in The Netherlands. RESULTS: A total of 136 patients were studied. The mean total costs were euro17,931 per patient. SREs that required hospitalization (n = 53) were, at median costs of euro2039-9346, depending on care. These SREs had median costs of euro200-1912. CONCLUSION: Our data provide a basis to investigate the cost-effectiveness of novel treatment options for metastatic prostate cancer. The impact of SREs on total costs could justify policy aimed at actively preventing SREs, possibly resulting in better quality of life and cost-reduction.